Aggregated price index with volume information
- Medical Distributors stocks down 0.2% on average while median return down -0.4% in a day
- Medical Distributors stocks up 5.9% on average while median return up 2.9% in a week
- Medical Distributors stocks up 8.0% on average while median return up 4.4% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $APLS 38.4%, $HSIC 12.0%, $OMI 10.9%, $CAH 6.9%
- 1M losers are : Losers for past month are $HLF -2.0%, $PDCO -14.6%, $ACET -26.7%
- 1W winners are : Winners for past week are $APLS 37.4%, $OMI 12.7%, $ACET 9.0%, $HSIC 3.7%
- 1W losers are : Losers for past week are $MCK -0.2%, $PDCO -15.4%
Index correlation analysis
Correlation for the past month is 7.9%, for the past 3 months is 9.2%
In the past month for a 5 days rolling window, the highest corrrelation is 32.9%, the lowest correlation is -8.3%, the latest correlation is 24.7%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 67.7% between CAH and OMI
The lowest correlation is -56.5% between CAH and HLF
Patterson Companies (PDCO) collaborates with dental AI solution provider, Pearl, to integrate the latter's Second Opinion software solution within its Eaglesoft software to deliver advanced solutions.
ST. PAUL, Minn., November 21, 2023--Patterson Companies (Nasdaq: PDCO) today announced that it will hold its fiscal 2024 second-quarter call on Wednesday, November 29, 2023, at 7:30 a.m. CT (8:30 a.m. ET). The company’s earnings release will be issued that morning before the market opens.
Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS therapy for lasting pain relief, enhanced function, quality of life and reduced opioid dependency.
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company will host a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:00 a.m. ET. The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. Abo
Days after posting the Class 1 recall notice, the FDA said changes made to certain syringes could lead to overdose, underdose, or delays in therapy or alarms.
LOS ANGELES, November 20, 2023--Patterson Dental Selects Pearl as New Integrated AI Provider.
The U.S. Food and Drug Administration on Monday warned healthcare providers and facilities not to use Cardinal Health's Monoject syringes with patient-controlled pain management pumps and syringe pumps. The regulator's warning comes after Cardinal Health initiated a recall for its Monoject syringes due to incompatibility concerns with syringe pumps. Monoject syringes are used to inject into or withdraw fluids from the body while patient-controlled analgesia, or pain management pumps, are used ...
Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
In this piece, we will take a look at the 12 stocks that billionaire Larry Robbins just bought and sold. If you want to skip our introduction to the billionaire hedge fund boss and the latest stock market news, then take a look at 5 Stocks Billionaire Larry Robbins Just Bought and Sold. Larry Robbins […]
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for mCRC.